ATE459642T1 - Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat - Google Patents

Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat

Info

Publication number
ATE459642T1
ATE459642T1 AT05763889T AT05763889T ATE459642T1 AT E459642 T1 ATE459642 T1 AT E459642T1 AT 05763889 T AT05763889 T AT 05763889T AT 05763889 T AT05763889 T AT 05763889T AT E459642 T1 ATE459642 T1 AT E459642T1
Authority
AT
Austria
Prior art keywords
chlorotoxin
myeloid
diagnosis
derivative
treatment
Prior art date
Application number
AT05763889T
Other languages
English (en)
Inventor
Vernon Alvarez
Matthew Gonda
Original Assignee
Transmolecular Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmolecular Inc filed Critical Transmolecular Inc
Application granted granted Critical
Publication of ATE459642T1 publication Critical patent/ATE459642T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT05763889T 2004-04-06 2005-04-06 Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat ATE459642T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55943304P 2004-04-06 2004-04-06
PCT/US2005/011523 WO2005099774A2 (en) 2004-04-06 2005-04-06 Diagnosis and treatment of myeloid and lymphoid cell cancers

Publications (1)

Publication Number Publication Date
ATE459642T1 true ATE459642T1 (de) 2010-03-15

Family

ID=35150508

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05763889T ATE459642T1 (de) 2004-04-06 2005-04-06 Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat

Country Status (9)

Country Link
US (1) US20110311445A1 (de)
EP (1) EP1756270B1 (de)
JP (2) JP2007532879A (de)
AT (1) ATE459642T1 (de)
AU (1) AU2005232616A1 (de)
CA (1) CA2561494A1 (de)
DE (1) DE602005019728D1 (de)
ES (1) ES2339683T3 (de)
WO (1) WO2005099774A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2360519T3 (es) 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
JP2011520914A (ja) 2008-05-15 2011-07-21 トランスモレキュラー， インコーポレイテッド 転移腫瘍の処置
HUE034119T2 (en) 2010-02-04 2018-01-29 Morphotek Inc Chlorotoxin polypeptides and conjugates and their use
WO2011142858A2 (en) 2010-05-11 2011-11-17 Fred Hutchinson Cancer Research Center Chlorotoxin variants, conjugates, and methods for their use
WO2013003507A1 (en) 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
RU2473901C1 (ru) * 2012-02-22 2013-01-27 Федеральное государственное бюджетное учреждение науки "Кировский научно-исследовательский институт гематологии и переливания крови Федерального медико-биологического агентства" Способ быстрой диагностики перевиваемого пролимфоцитарного лейкоза у мышей линии akr/jy
BR112015013525A2 (pt) 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
KR20170021354A (ko) * 2014-07-02 2017-02-27 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) CD1d 제한된 감마/델타 T 세포 림프종을 진단 및 치료하는 방법
JP7080478B2 (ja) * 2017-09-14 2022-06-06 株式会社西部技研 ガス置換用ドライルーム
JP7409741B2 (ja) 2017-09-15 2024-01-09 エーザイ インク． クロロトキシン薬剤及びその使用
US11866466B2 (en) 2017-12-19 2024-01-09 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002345959A1 (en) * 2001-06-26 2003-01-08 Uab Research Foundation Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
WO2003101474A1 (en) * 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
AU2004256425A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer

Also Published As

Publication number Publication date
JP2011149961A (ja) 2011-08-04
EP1756270A4 (de) 2007-10-24
EP1756270A2 (de) 2007-02-28
US20110311445A1 (en) 2011-12-22
EP1756270B1 (de) 2010-03-03
WO2005099774A3 (en) 2006-03-23
WO2005099774A2 (en) 2005-10-27
DE602005019728D1 (de) 2010-04-15
JP2007532879A (ja) 2007-11-15
CA2561494A1 (en) 2005-10-27
ES2339683T3 (es) 2010-05-24
AU2005232616A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
ATE459642T1 (de) Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat
ATE424416T1 (de) Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
BRPI0507984A (pt) composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto
ATE325343T1 (de) Diagnose und behandlung von arthritischen erkrankungen
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
EA200870088A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов и глюкозы в крови
NO20054361L (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
BRPI0518000A (pt) tetrahidroisoquinolinas aril- e heteroaril- substituìdas e uso das mesmas para bloquear a reabsorção de norepinefrina, dopamina e serotonina
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
TNSN07165A1 (en) Organic compounds
EA200702583A1 (ru) Использование фенилсемикарбазонов для обработки семян
ATE452134T1 (de) Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
ATE359087T1 (de) Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
MY146920A (en) Aminothiazole derivatives and their uses as antibacterial agents
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
Mohite et al. Differential trend of leprosy in rural and urban area of Western Maharashtra
EA201001427A1 (ru) Тиазолилдигидроиндазолы
DE10390950D2 (de) Vorrichtung zur Behandlung von Patienten mittels Hirnstimulation
EA200701584A1 (ru) Органические соединения, применяемые для лечения болезни альцгеймера, их применение и способ получения
DE60325965D1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen
BRPI0507745A (pt) compostos de azetidina substituìda como inibidores de ciclooxigenase-1-ciclooxigenase-2, processo para a sua preparação, medicamentos e seus usos
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
BR0215583A (pt) Tratamento profilático e terapêutico de doenças infecciosas e outras com compostos imunoefetores

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties